EUCLID 1997

Methods	Country: UK Setting/Design: University Time frame: NS Randomisation method: Yes Blinding ‐ Participants: Yes ‐ Investigators: Yes ‐ Outcome assessors: No ‐ Data analysis: No Intention‐to‐treat: Yes Follow‐up period: 24 months Loss to follow‐up: 82
Participants	Inclusion criteria Age: 20‐59 years Males and females DM: Type 1 (diagnosis before age 36 and the need for continuous insulin therapy within a year of diagnosis) Resting DBP: 75‐90 mm Hg and SBP </= 155 mm Hg Lisinopril group Number: 265 Age: 33 (27‐40) Sex (M/F): 155/110 Placebo group Number: 265 Age: 33 (28‐41) Sex (M/F): 167/98 Exclusion criteria History of renal‐artery stenosis, cardiac‐valve obstruction, or accelerated hypertension Recent (within the previous 3 months) MI, coronary bypass surgery, stroke, or CHF Abnormal renal function: SCr > 1.8 mg/dL in the previous 6 months, persistent proteinuria (albustix positive or an AER > 250 µg/min) or persistent haematuria on 3 occasions within the previous 12 months Postural hypotension Medication that affects BP Previous idiosyncratic reaction to ACEi Seropositive for hepatitis B or HIV
Interventions	Lisinopril group 10‐20 mg/d Placebo group Co‐interventions: NS
Outcomes	AER
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A ‐ Adequate